Collegium PharmaceuticalFRA:354 75 Gross Margin % is 60.59% as of Mar. 2026, which is 5% above its 10-year median of 57.78. GuruFocus rates FRA:354 with a GF Score™ of 75/100 and a GF Value™ of €37.18 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 937 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 70.01% on this metric.
Collegium Pharmaceutical (FRA:354) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Collegium Pharmaceutical had a gross margin of 60.59% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Collegium Pharmaceutical Gross Margin % Related Terms
Collegium Pharmaceutical Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:354 vs ALVO, PAHC, BIOA: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Collegium Pharmaceutical (FRA:354) has a Gross Margin % of 60.59% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Collegium Pharmaceutical and its competitors. This is near median its historical median of 57.78. Over the past decade, Collegium Pharmaceutical's Gross Margin % has ranged from 34.73 to 90.89. According to the industry distribution chart, Collegium Pharmaceutical ranks #281 out of 937 companies in the Drug Manufacturers industry, placing it in the top 30%.
Is Collegium Pharmaceutical's Gross Margin % too high?
Collegium Pharmaceutical's current Gross Margin % of 60.59% is near median its 10-year median of 57.78. Over the past 10 years, this metric has ranged from a low of 34.73 to a high of 90.89. The Drug Manufacturers industry median Gross Margin % is 48.46. Collegium Pharmaceutical's value of 60.59% is 25% above this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #281 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Collegium Pharmaceutical has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Gross Margin % compare to ALVO and PAHC?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #281 out of 937 companies for Gross Margin %. This puts Collegium Pharmaceutical in the upper half of its industry. The industry median Gross Margin % is 48.46. Collegium Pharmaceutical's value of 60.59% is 25% above this benchmark. Historically, Collegium Pharmaceutical's own Gross Margin % has ranged from 34.73 to 90.89 over the past decade. While the company's 10-year median is 57.78 vs. the industry median of 48.46, Collegium Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current Gross Margin % of 60.59% is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current Gross Margin % is 60.59%, which is near median its own 10-year median of 57.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (FRA:354) is currently considered Modestly Undervalued. The stock's GF Value™ is €37.18, compared to a current price of €31.20 — trading 16.1% below its estimated fair value. The current Gross Margin % is 60.59%, which is near median its 10-year median of 57.78 and 25% above the Drug Manufacturers industry median of 48.46. Collegium Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current Gross Margin % is 60.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of €31.20 is trading 16.1% below its estimated GF Value™ of €37.18.
GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.
Key valuation signals for FRA:354:
Gross Margin %: 60.59% (near median its 10-year median of 57.78)
GF Value™: €37.18 vs. price of €31.20 (16.1% below fair value)
Industry Position: 25% above the Drug Manufacturers median (#281 of 937)
No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
75GF Score
Get the complete analysis for FRA:354
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:354 has been successfully added to your 
